PTPRD and metastatic squamous cell carcinoma: Furthermore, treatment with everolimus and pazopanib led to a partial response for 18.2 months in one patient with metastatic squamous cell carcinoma that harbored PIK3CA (E545K), PTPRD (S1845fs*2), and STK11 losses.